Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 2, March-April, p. 233–237

doi: 10.17219/acem/40448

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Association of Endogenous Melatonin with Uric Acid and Traditional Cardiovascular Risk Factors in Healthy Young Male

Banu S. Yildiz1,A,D,E,F, Alparslan Sahin2,A,B,D,F, Nazire B. Aladag1,B,C,F, Mustafa Yildiz3,A,D,E,F

1 Department of Internal Medicine, Dr Lutfi Kirdar Kartal Educational and Research Hospital, Istanbul, Turkey

2 Department of Cardiology, Bakirkoy Dr. Sadi Konuk Educational and Research Hospital, Istanbul, Turkey

3 Department of Cardiology, Kartal Kosuyolu Yuksek Ihtisas Educational and Research Hospital, Istanbul, Turkey

Abstract

Background. Uric acid may act as an antioxidant; high serum uric acid levels are often associated with cardiovascular disease, such as coronary artery disease. Melatonin plays a role as a direct free radical scavenger and indirect antioxidant. No study has examined the relationships between endogenous melatonin and uric acid in order to predict the risk of future cardiovascular disease in male so far. To better characterize a possible relationship, we studied the association of endogenous melatonin with uric acid and traditional cardiovascular risk factors such as plasma lipids, and glucose in healthy young male.
Material and Methods. Twenty-one male participants [mean age: 22.6 2.5 (18–26) year], non-smoking; their medication or alcohol consumption history were studied. Blood samples for measuring melatonin concentrations were collected in the supine position between 13:30–14:30 hours. After centrifugation, plasma samples were immediately frozen at –20°C until analysis.
Results. Although we found a significant negative correlation between the levels of endogeneous melatonin and uric acid (p = 0.01, r = –0.51), we did not find any correlation among the melatonin and other antropometric, hemodynamic and biochemical parameters in male subjects (p > 0.41).
Conclusion. The present study demonstrated that a significant negative correlation between the levels of endogeneous melatonin and uric acid in healthy young male.

Key words

melatonin, uric acid, traditional cardiovascular risk factors, healthy young male.

References (25)

  1. Pasalic D, Marinkovic N, Feher-Turkovic L: Uric acid as one of the important factors in multifactorial disorders – facts and controversies. Biochem Med (Zagreb) 2012, 22, 63–75.
  2. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008, 359, 1811–1821.
  3. Fang J, Alderman MH: Serum uric acid and cardiovascular mortality – the NHANES I epidemiologic follow-up study, 1971–1992. JAMA 2000, 283, 2404–2410.
  4. Borjigin J, Zhang LS, Calinescu AA: Circadian regulation of pineal gland rhythmicity. Mol Cell Endocrinol 2012, 349, 13–19.
  5. Arendt J: Melatonin. J Clin Endocrinol Metab 1988, 29, 205–229.
  6. Yildiz M, Akdemir O: Assessment of the effects of physiological release of melatonin on arterial distensibility and blood pressure. Cardiol Young 2009, 19, 198–203.
  7. Reiter RJ, Tan DX, Osuna C, Gitto E: Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000, 7, 444–458.
  8. Pilaczyńska-Szcześniak L, Karolkiewicz J, Strzelczyk A, Stankiewicz K, Osiński W, Stemplewski R, Szeklicki R: Melatonin concentrations and other parameters of blood antioxidant defense system in elderly men with various levels of physical activity. Pol Arch Med Wewn 2004, 111, 557–562.
  9. Schulz E, Gori T, Münzel T: Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 2011, 34, 665–673.
  10. Bergamini C, Cicoira M, Rossi A, Vassanelli C: Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 2009, 11, 444–452.
  11. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67, 1739–1742.
  12. Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN: Inactivation of nitric oxide by uric acid. Nucleos Nucleot Nucl 2008, 27, 967–978.
  13. Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER, Patel J: Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008, 295, 1183–1190.
  14. Reiter RJ, Craft CM, Johnson JE Jr, King TS, Richardson BA, Vaughan GM, Vaughan MK: Age-associated reduction in nocturnal pineal melatonin levels in female rats. Endocrinology 1981, 109, 1295–1297.
  15. Sewerynek E: Melatonin and the cardiovascular system. Neuro Endocrinol Lett 2002, 23, Suppl 1, 79–83.
  16. Yaprak M, Altun A, Vardar A, Aktoz M, Ciftci S, Ozbay G: Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int J Cardiol 2003, 89, 103–107.
  17. Domínguez-Rodríguez A, Abreu-González P, García MJ, Sanchez J, Marrero F, de Armas-Trujillo D: Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 2002, 33, 248–252.
  18. Pieri C, Marra M, Moroni F, Recchioni R, Marcheselli F: Melatonin: a peroxyl free radical scavenger more effective than vitamin E. Life Sci 1994, 55, 271–276.
  19. Reppert SM: Melatonin receptors: molecular biology of a new family of G protein coupled receptors. J Biol Rhythms 1997, 12, 528–531.
  20. Brydon L, Petit L, Delagrange P, Strosberg AD, Jockers R: Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. Endocrinology 2001, 142, 4264–4271.
  21. Paparrigopoulos T, Psarros C, Bergiannaki J, Varsou E, Dafni U, Stefanis C: Melatonin response to clonidine administration in depression: indication of presynaptic alpha2-adrenoceptor dysfunction. J Affect Disord 2001, 65, 307–313.
  22. Masue T, Wada K, Hayashi M, Takeda N, Yasuda K, Deguchi T, Nagata C: Associations of urinary 6-sulfatoxymelatonin with biomarkers related to cardiovascular disease in Japanese women. Metabolism 2012, 61, 70–75.
  23. Markantonis SL, Tsakalozou E, Paraskeva A, Staikou C, Fassoulaki A: Melatonin pharmacokinetics in premenopausal and postmenopausal healthy female volunteers. J Clin Pharmacol 2008, 48, 240–245.
  24. Parry BL, Meliska CJ, Sorenson DL, Martínez LF, López AM, Elliott JA, Hauger RL: Reduced phase-advance of plasma melatonin after bright morning light in the luteal, but not follicular, menstrual cycle phase in premenstrual dysphoric disorder: an extended study. Chronobiol Int 2011, 28, 415–424.
  25. Shechter A, Varin F, Boivin DB: Circadian variation of sleep during the follicular and luteal phases of the menstrual cycle. Sleep 2010, 33, 647–656.
© Wroclaw Medical University